We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Show more
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24...
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.21 | 5.27923211169 | 22.92 | 24.88 | 22.39 | 309463 | 23.54542894 | CS |
4 | 1.92 | 8.64475461504 | 22.21 | 24.88 | 21.34 | 196426 | 22.79565343 | CS |
12 | 2.59 | 12.0241411328 | 21.54 | 27.6731 | 20.825 | 203075 | 23.58136209 | CS |
26 | 6.35 | 35.7142857143 | 17.78 | 27.6731 | 15.96 | 284987 | 22.11820613 | CS |
52 | 9.84 | 68.8593421973 | 14.29 | 27.6731 | 9.8 | 209035 | 19.47731153 | CS |
156 | -0.07 | -0.289256198347 | 24.2 | 27.6731 | 9.8 | 191935 | 19.5855784 | CS |
260 | -0.07 | -0.289256198347 | 24.2 | 27.6731 | 9.8 | 191935 | 19.5855784 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions